- Advertise
- Contact Us
- Contribute
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
- About Us
© 2022 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
Cardiology
The Endocrinology Network® Cardiology clinical resource center is a hub of news related to cardiovascular health that is relevant to clinicians interested in endocrinology. This page will host relevant content about cardiology and cardiovascular disease including guideline updates, new studies and breakthroughs, and clinical perspectives for practicing clinicians.
COVID-19 Infection Could Increase Risk of Developing Diabetes
July 19, 2022
An analysis of data from more than 450,000 patients in the UK details an 81% increase in the net incidence of diabetes in the first 4 weeks after contracting COVID-19, which remained elevated through weeks 5-12, compared to those who did not contract COVID-19.
Study Draws Attention to Poor Levels of Cardiometabolic Health in US Adults
July 06, 2022
An analysis of nationally representative data from NHANES cycles from 1999-2000 through 2017-2018 suggests just 6.8% of US adults had optimal cardiometabolic health.
Diabetes Mellitus Accelerates Heart Failure Progression
June 23, 2022
Dr. Gregory Weiss provides perspective on recent data detailing the acceleration of heart failure progression associated with a diagnosis of diabetes mellitus.
PCOS Increases Risk for Cardiovascular Complications During Delivery
June 22, 2022
Data from a Johns Hopkins Medicine-led analysis provide insight into the risk of cardiovascular complications among women with polycystic ovary syndrome during delivery hospitalizations compared to their counterparts without PCOS.
Increased PFAS Exposure Linked to High Blood Pressure in Aging Women
June 18, 2022
According to a new study, cumulative exposure to PFAS during midlife can increase the risk of incident hypertension among women as they age, with those in the highest tertile of cumulative exposure at a 71% greater risk of developing hypertension.
Prediabetes Linked to Increased Risk of Myocardial Infarction
June 13, 2022
An analysis of the National Inpatient Sample at ENDO 2022 provides insight into the risk of myocardial infarction associated with prediabetes compared against normoglycemic patients.
Time to Rethink Metformin as First-Line Therapy? Perspective from ADA 2022
June 06, 2022
After new data from the Diabetes Prevention Program Outcomes Study suggested neither metformin nor lifestyle intervention addressed the cardiovascular risk in patients with prediabetes, we asked experts at ADA 2022 if it was time to rethink metformin as first-line therapy in type 2 diabetes.
EMPRISE: Empagliflozin Bests GLP-1 RAs, DPP-4 Inhibitors for Reducing Heart Failure Hospitalizations
June 05, 2022
A 5-year, real-world study comparing the safety and efficacy of empagliflozin against other glucose-lowering agents, EMPRISE suggests empagliflozin was associated with relative risk reductions for heart failure hospitalization greater than 50% compared with DPP-4 inhibitors and greater than 30% compared with GLP-1 receptor agonists.
Navigating a Changing Landscape: ADA Standards Embrace CV, Renal Benefits of Newer Agents
June 03, 2022
Naomi Fisher, MD, offers perspective on the changing landscape of diabetes management and how the addition of new agents to the ADA's Standards of Care might impact care of patients.
Endocrine Month in Review: May 2022
May 28, 2022
Our endocrine month in review spotlights the most popular articles from the past month. This month's top articles include the approval of tirzepatide, news from AACE & ATTD, and a pair of podcast episodes.